KAPA (Kairos Pharma) EBITDA Margin %: 0.00% (As of Mar. 2026)


KAPA Kairos Pharma Ltd KAPA
15 GF Score
Price $0.38
View Full Analysis

What is Kairos Pharma EBITDA Margin %?

Kairos Pharma KAPA +7.48% 15 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates KAPA with a GF Score™ of 15/100. Among 942 Biotechnology companies, Kairos Pharma ranks worse than 106157.01% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kairos Pharma's EBITDA for the three months ended in Mar. 2026 was $-1.65 Mil. Kairos Pharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Kairos Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Kairos Pharma  (AMEX:KAPA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Kairos Pharma EBITDA Margin % Related Terms

Kairos Pharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Kairos Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kairos Pharma EBITDA Margin % Chart

Kairos Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Kairos Pharma Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

KAPA vs IMNN, HCWB, CURX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Kairos Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kairos Pharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kairos Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Kairos Pharma's EBITDA Margin % falls into.


KAPA
15GF Score
Kairos Pharma Ltd KAPA
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kairos Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Kairos Pharma's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-5.287/0
= %

Kairos Pharma's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.65/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Kairos Pharma (KAPA) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kairos Pharma and its competitors. According to the industry distribution chart, Kairos Pharma ranks #999999 out of 942 companies in the Biotechnology industry.
Is Kairos Pharma's EBITDA Margin % too high?
Kairos Pharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, Kairos Pharma ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kairos Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Kairos Pharma's EBITDA Margin % compare to IMNN and HCWB?
According to the Biotechnology industry distribution chart, Kairos Pharma ranks #999999 out of 942 companies for EBITDA Margin %. This places Kairos Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kairos Pharma and its competitors. Kairos Pharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kairos Pharma stock overvalued right now?
Kairos Pharma (KAPA) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Kairos Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kairos Pharma (KAPA), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kairos Pharma Business Description

Address 2355 Westwood Boulevard, No. 139, Los Angeles, CA, USA, 90064
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score

Get the complete analysis for KAPA

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price